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Abstract
Tyrosinemia type 1 (TT1) is a rare metabolic disease caused by a defect in tyrosine catabolism. TT1 is clinically character-
ized by acute liver failure, development of hepatocellular carcinoma, renal and neurological problems, and consequently an 
extremely poor outcome. This review showed that the introduction of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexane-
dione (NTBC) in 1992 has revolutionized the outcome of TT1 patients, especially when started pre-clinically. If started early, 
NTBC can prevent liver failure, renal problems, and neurological attacks and decrease the risk for hepatocellular carcinoma. 
NTBC has been shown to be safe and well tolerated, although the long-term effectiveness of treatment with NTBC needs 
to be awaited. The high tyrosine concentrations caused by treatment with NTBC could result in ophthalmological and skin 
problems and requires life-long dietary restriction of tyrosine and its precursor phenylalanine, which could be strenuous to 
adhere to. In addition, neurocognitive problems have been reported since the introduction of NTBC, with hypothesized but 
as yet unproven pathophysiological mechanisms. Further research should be done to investigate the possible relationship 
between important clinical outcomes and blood concentrations of biochemical parameters such as phenylalanine, tyrosine, 
succinylacetone, and NTBC, and to develop clear guidelines for treatment and follow-up with reliable measurements. This 
all in order to ultimately improve the combined NTBC and dietary treatment and limit possible complications such as hepa-
tocellular carcinoma development, neurocognitive problems, and impaired quality of life.
Key Points 
Treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-
1,3-cyclohexanedione (NTBC) has been found to be 
generally safe and has clearly improved treatment and 
outcomes for patients with tyrosinemia type 1.
The long-term risks for complications associated with 
tyrosinemia type 1 or treatment with NTBC are not yet 
fully known and therefore strict follow-up is necessary.
Future challenges include the development of uniform 
guidelines for treatment and follow-up, and weighing the 
risks, challenges, and costs of existing and alternative 
strategies for the treatment of tyrosinemia type 1.
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1 Introduction
Tyrosinemia type 1 (TT1; OMIM276700), also called 
hepatorenal tyrosinemia, is an inborn error of metabolism, 
caused by an autosomal recessive inherited deficiency of the 
enzyme fumarylacetoacetate hydrolase (FAH), which is the 
last enzyme in the tyrosine catabolic pathway converting 
fumarylacetoacetate (FAA) into fumarate and acetoacetate. 
One of the first patients described with TT1 presented with 
liver cirrhosis, renal tubular defects, and vitamin D-resistant 
rickets, although the exact diagnosis was not clear at that 
time [1]. Initially, the primary enzyme defect was consid-
ered to be a defect of 4-hydroxyphenylpyruvate dioxygenase 
(4HPPD) [2, 3]. Some years later, it became apparent that 
the primary enzyme deficiency was located more down-
stream in the catabolic pathway of tyrosine at FAH (Fig. 1) 
[4].
The only existing treatment at that time was dietary 
restriction of tyrosine and its precursor phenylalanine. 
Unfortunately, when only treated with a phenylalanine/
tyrosine-restricted diet, the outcome was extremely poor. 
Many TT1 patients did not survive the initial period when 
presenting with severe liver failure and its associated prob-
lems, including ascites and bleeding [5]. If patients survived 
this period, many died years later due to the development 
of hepatocellular carcinoma (HCC) or respiratory failure 
caused by porphyria-like syndrome [5–7]. As a consequence, 
orthotopic liver transplantation (OLT) was long considered 
the only definitive option to treat the metabolic as well as 
the oncological problem [8–10].
This all changed after the introduction of 2-(2-nitro-
4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC, 
also known as nitisinone) as a new treatment option in 1992 
[11]. NTBC proved to be a potent inhibitor of the enzyme 
4HPPD, which was first thought to be responsible for the 
disease. In this way, NTBC can prevent the production of 
the toxic metabolites FAA, maleylacetoacetate, succinylace-
toacetate, and succinylacetone (SA), and thereby substan-
tially improves the clinical outcome [12, 13]. However, as 
a consequence of 4HPPD inhibition by NTBC treatment, 
tyrosine concentrations increase substantially further, mak-
ing a phenylalanine/tyrosine-restricted diet again part of the 
treatment of TT1 [14].
It is now more than 25 years since NTBC was introduced 
as a treatment option. Since then, many TT1 patients have 
been treated with NTBC, most of them in combination with 
the phenylalanine/tyrosine-restricted diet. Many living TT1 
patients are diagnosed after presentation with the associated 
symptoms, although patients are diagnosed increasingly by 
population-based newborn screening. This review aims to 
address the outcome of TT1 patients and long-term consid-
erations in the pharmacological treatment of TT1 patients.
2  NTBC and its Pharmacodynamics 
and Pharmacokinetics
Naturally occurring triketones are produced by a num-
ber of plants and lichens. They are synthesized to prevent 
growth of surrounding plants [15, 16]. NTBC is such a 
triketone and was one of the first to be used as a herbicide 
[17]. Experiments revealed that NTBC is a strong inhibitor 
of the enzyme 4HPPD [18–20], the second enzyme in the 
catabolic cascade of tyrosine. 4HPPD catalyzes the conver-
sion of 4-hydroxyphenylpyruvate to homogentisate (Fig. 1). 
Through NTBC-mediated inhibition of the production of 
homogentisate, the synthesis of tocopherols and plastoqui-
nones in plants is blocked, thereby reducing the production 
of chlorophyll. In this way, NTBC causes plants to bleach 
[18]. In humans, it was postulated that NTBC could block 
further catabolism of tyrosine into its degradation products 
[11].
The enzyme 4HPPD is a dioxygenase as its reaction 
utilizes diatomic oxygen for oxidative decarboxylation as 
well as aromatic ring hydroxylation [21]. NTBC rapidly and 
tightly binds to the Fe(II)-containing active site of 4HPPD 
after a multi-step process. Both NTBC and the substrate 
4-hydroxyphenylpyruvate have similar binding interac-
tions, with NTBC especially showing close affinity to the 
enzyme caused by interactions such as π-stacking. The 
binding causes a rapid inactivation of the enzyme by creat-
ing an almost irreversible 4HPPD inhibitor complex [20, 
22–24]. In vitro experiments with tissue of wild-type rats 
revealed that a concentration of only 100 nM of NTBC was 
sufficient to block > 90% of the enzyme activity, with only a 
small amount of activity returning after 7 h [19]. This strong 
inhibitory reaction was also seen in healthy adult human 
participants, with a plasma half-life of 54 h after a single 
dose of NTBC [25].
In rats, NTBC showed a general tissue distribution pattern 
shortly after dosing, with NTBC detectable in many different 
tissues including plasma, eye (cornea and glands), liver, kid-
neys, lung, and a small amount in the brain [26]. However, 
retention of NTBC was especially apparent in the liver and 
kidneys of the investigated wild-type rats and mice [26, 27]. 
NTBC is excreted in urine and feces, each accountable for 
about 50% of the excretion. In urine, NTBC was excreted 
unchanged, as 4- or 5-hydroxy metabolites, as amino acid 
conjugate, or as 2-nitro-4-trifluoromethylbenzoic acid after 
hydrolytic cleavage, while three unidentified metabolites 
were detected in rat fecal extracts [28–30].
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3  Practical Management of NTBC Treatment 
in Tyrosinemia Type 1 (TT1)
As NTBC inhibits the enzyme 4HPPD, it was considered 
to be a potential treatment for TT1 patients by creating a 
metabolic block upstream from the primary enzymatic 
defect. Lindstedt et  al. [11] were the first to treat TT1 
patients with NTBC. The first five patients were treated with 
NTBC 0.1–0.2 mg/kg/day, which was gradually increased 
to 0.4–0.6 mg/kg/day. Treatment with NTBC led to a tre-
mendous improvement of hallmark biochemical abnormali-
ties, including a decrease in urine and blood SA concentra-
tions, improvement of porphobilinogen synthase activity in 
erytrocytes and lower urine 5-aminolevulinic acid (5-ALA) 
concentrations. As a consequence, resulting clinical symp-
toms such as liver failure and kidney problems improved 
[11].
Nowadays, the recommendation in Europe, the US, and 
Canada is to treat patients with 1 mg/kg/day [14, 31–33], 
although there is some advice to start with 2 mg/kg/day in 
case of acute liver failure [14], while chronic treatment in 
stable patients is sometimes given at much lower NTBC 
doses of around 0.36–0.6 mg/kg/day [34–36]. Some reports 
state that NTBC once a day is enough as blood concentra-
tions tend to be stable for at least 24 h [14, 25, 37, 38], while 
others favor giving NTBC twice a day to adequately prevent 
raised bloodspot SA concentrations [33, 39]. In addition, 
Fig. 1  Phenylalanine and tyrosine degradation pathway is shown 
with the different enzymes and corresponding associated metabolic 
disorders, namely phenylketonuria (PKU), tyrosinemia type 2 (TT2), 
tyrosinemia type 3 (TT3), hawkinsinuria, alkaptonuria (AKU), 
maleylacetoacetate isomerase deficiency (MAAID), and tyrosinemia 
type 1 (TT1)
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the optimal time for blood sampling is not known and may 
be dependent on the timing of NTBC administration [39].
Dose optimization of NTBC could be done based on 
several (indirect) parameters, such as (i) doses individually 
adjusted to mg/kg body weight, (ii) porphobilinogen syn-
thase activity in erythrocytes, (iii) plasma 5-ALA concen-
trations, (iv) plasma or blood spot NTBC concentrations, or 
(v) urine, plasma, or blood spot SA concentrations [11, 12]. 
Unfortunately, recommendations for target blood spot NTBC 
concentrations are hampered by large inter- and intraindivid-
ual variabilities and lack of standardization of NTBC assays 
[36, 37, 40–44]. Therefore, target blood NTBC concentra-
tions vary mostly between 30 and 60 µmol/L, although con-
centrations ranging between 20 and 150 µmol/L have been 
reported [14, 32–34, 40, 45, 46]. A detectable or increased 
SA concentration in blood spots or plasma, or its excretion 
in urine, is considered to be a sensitive indicator for subop-
timal NTBC treatment and reason for adjustment of therapy 
[32, 33]. Urine was long considered to be the preferred 
matrix, mainly because analytical methods were not sensi-
tive enough to analyze the low SA concentrations in plasma 
or blood spots. However, new techniques have led to a clear 
improvement in sensitivity [47]. There is currently no con-
sensus on the preferred matrix for monitoring SA. A further 
increase in the sensitivity of the analytical methods allowed 
a few laboratories to detect SA in blood spots in healthy indi-
viduals, which was previously unnoticed. Therefore, with 
NTBC treatment, SA concentrations should be targeted to 
the reference range, but its clinical relevance clearly needs 
to be established in the coming years [32, 48].
To date, there have been only a few reports about adher-
ence to NTBC. One study reported a high level of adherence 
to the NTBC medication, with only 1 day of reported non-
adherence in a 10-week period [49], while others reported 
adherence problems in about 15% of the patients [50, 51]. 
Single cases reported that discontinuation of NTBC for 
1–8 weeks resulted in severe, life-threatening neurological 
crises with diaphragm paralysis and respiratory failure [46, 
52–56]. However, it is not known whether the use of NTBC 
was already suboptimal for a longer period of time in these 
patients. It could be hypothesized that long-term suboptimal 
use of NTBC is the most important reason for later develop-
ment of HCC, as has been reported in TT1 mice [57]. Regu-
lar measurement of NTBC and SA in blood spots [36, 39, 
40, 42, 47] might increase treatment adherence and therapy 
adjustment accordingly. Further investigation on optimal 
treatment regimens and cut-off values for biomarkers are 
therefore essential.
4  NTBC Treatment in Other Disorders 
of Tyrosine Metabolism
As NTBC inhibits the enzyme 4HPPD, it could not only be 
useful in TT1 but in other disorders of tyrosine metabolism 
caused by an enzymatic defect downstream from 4HPPD 
as well. Alkaptonuria (AKU), caused by a deficiency of 
homogentisate dioxygenase, is one of them (Fig. 1). AKU is 
characterized by high homogentisic acid concentrations that 
could result in depositions in connective tissue among oth-
ers, leading to spondyloarthropathy, cardiac valve disease, 
stone formation, and osteopenia [58, 59]. A total daily dose 
of only 2 mg NTBC already resulted in 95% reduction of 
urinary homogentisic acid [60, 61]. Interestingly, this NTBC 
dose is much lower than the dose given to TT1 patients. 
This could at least partly be explained as the aim in TT1 is 
to have no activity of 4HPPD at all, while this is different 
in AKU. Although this low dose of NTBC initially failed 
to show a response on non-biochemical outcomes [60], a 
decrease in clinical progression of eye and ear ochronosis in 
AKU patients has recently been reported [62, 63]. It is not 
known whether long-term NTBC treatment in AKU is effec-
tive, neither is it known whether NTBC could prevent the 
severe bone disease caused by ochronosis in AKU patients 
if started early.
Maleylacetoacetate isomerase deficiency (MAAID) 
(Fig. 1) has only been found and reported rarely. MAAID is 
responsible for the conversion of maleylacetoacetate to FAA 
and is characterized by relatively mildly increased plasma 
and urine SA concentrations and a normal amino acid profile 
[64]. The first reported patient with proven MAAID had 
severe liver and renal failure. However, a favorable out-
come without any liver or renal disease has recently been 
described in six untreated MAAID patients [64]. This is 
in agreement with the MAAID knockout mice that under 
normal circumstances did not show a clinical phenotype, 
although liver and renal damage could be induced by a phe-
nylalanine-enriched diet [65]. Thus, it can’t be excluded that 
MAAID patients under certain circumstances could show 
liver and renal problems. However, for now there seems no 
need for NTBC in the regular treatment of MAAID.
Another rarely reported disease of tyrosine metabolism 
is hawkinsinuria. Hawkinsinuria is not caused by a defect 
downstream of 4HPPD like the previously mentioned dis-
eases, but is supposed to be caused by an autosomal domi-
nant mutation in the 4HPPD enzyme itself [66–68]. Next 
to hypertyrosinemia, this mutation causes the formation of 
hawkinsin instead of homogentisate [68]. It is not certain 
whether this defect always results in clear clinical manifesta-
tions, although transient metabolic acidosis during infancy 
with vomiting and diarrhea and consequently failure to 
thrive have been reported [69–73]. In rats, NTBC has shown 
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to inhibit the mutant 4HPPD enzyme in a similar way as 
the normal 4HPPD enzyme, indicating a possible treatment 
strategy for symptomatic infants with hawkinsinuria [68].
Apart from 4HPPD defects or defects downstream of 
4HPPD, phenylketonuria (PKU) could also be reasoned to 
benefit from NTBC treatment [74]. Due to the competitive 
effect on the blood–brain barrier, high plasma phenylalanine 
concentrations could, among others, lead to low brain tyros-
ine concentrations [75]. When increasing plasma tyrosine 
concentrations by NTBC, it could be reasoned that plasma 
phenylalanine:tyrosine ratios and consequently brain phe-
nylalanine, tyrosine, and dopamine concentrations improve. 
This in turn might improve the neurocognitive outcome 
[76–79]. Data from Harding et al. indeed showed that treat-
ment with NTBC in PKU mice led to a clear decrease in 
brain phenylalanine and increase in tyrosine and dopamine 
concentrations and could thus be an adjunct therapy in PKU 
[74].
5  Adverse Effects of NTBC
NTBC seems to be well tolerated with only a few reported 
adverse effects. One of the main concerns about the treat-
ment with NTBC are the eye problems associated with it. 
Most of the rats treated with NTBC soon developed corneal 
opacities [26]. The similarity between the corneal problems 
in NTBC-treated rats and rats fed with a tyrosine-enriched 
diet led to the conclusion that the corneal lesions are caused 
by the poor solubility of tyrosine and are thus secondary to 
the increase in tyrosine concentrations induced by NTBC 
rather than a toxic effect of NTBC itself [26, 80]. However, 
this could not be the only explanation as clear interspecies 
differences in ocular problems are found [27, 28, 81].
Due to the associated increase in tyrosine concentrations 
and secondary development of ocular problems, NTBC 
treatment has from the start been combined with a phenyla-
lanine/tyrosine-restricted diet [11]. Currently, treatment rec-
ommendations vary between different centers and countries, 
with upper tyrosine concentrations varying between 400 
and 600 µmol/L [14, 31–33, 82, 83], although higher levels 
up to 800 µmol/L are sometimes accepted in practice [45]. 
Despite the dietary restriction, eye problems are still found 
in approximately 5–10% of the TT1 patients [12, 31]. The 
most frequently reported eye problems are transient itching, 
burning, and photophobia [12, 31, 51], although silent kera-
topathy, clinical corneal opacities, or even corneal crystals 
presenting as pseudodendritic lesions have been reported 
[12, 46, 63, 84–87]. Although no clear correlation between 
ocular problems and tyrosine concentrations could be found, 
withdrawal of NTBC or stricter adherence to the phenyla-
lanine/tyrosine-restricted diet resolves the corneal lesions 
[12, 13, 87]. Therefore, ophthalmic follow-up is necessary 
and in case of eye problems, specific eye investigations with 
a slit lamp should be considered, while the diet should be 
intensified [82, 88].
In addition to high tyrosine concentrations caused by 
NTBC treatment, phenylalanine concentrations below the 
lower limit of normal are often found in TT1 patients [11, 
13, 89–92]. Although these low phenylalanine concentra-
tions are usually expected to be caused by the phenylalanine/
tyrosine-restricted diet, NTBC itself seems to lower plasma 
phenylalanine concentrations as well [74]. The mechanism 
by which NTBC treatment lowers plasma phenylalanine is 
not understood. Low phenylalanine concentrations have been 
associated with growth retardation, neurological impair-
ments, and skin problems in an infant with TT1 [91]. There-
fore, phenylalanine supplementation has been suggested to 
prevent these low phenylalanine concentrations, although 
the exact dosage and its effect on phenylalanine concentra-
tions is not clear yet [33, 89, 91, 93]. No uniform consensus 
guidelines exist, but the usual advice is to keep phenylala-
nine concentrations within the normal range (38–78 µmol/L) 
[32, 94]. Because of the expected drop in phenylalanine 
concentrations in the afternoon, we advised to keep fasting 
phenylalanine concentrations above 50 µmol/L [92].
Other reported adverse effects of NTBC are relatively 
uncommon, minor, and/or transient and usually do not 
require disruption of NTBC treatment. The most frequently 
reported adverse effects (except for ocular problems) are leu-
kopenia, thrombocytopenia, or granulocytopenia (all < 10%), 
and pruritus, exfoliative dermatitis, erythematous rash, myo-
clonia, or constipation (all < 1%) [12, 14, 45, 46, 50, 63, 95].
6  Outcome in TT1 Before and After 
Introduction of NTBC
6.1  Liver Problems
Especially FAA, but maybe also maleylacetoacetate, has 
been shown to be cytotoxic and mutagenic and causes glu-
tathione depletion, oxidative stress, chromosomal instability, 
cell cycle arrest, and apoptosis in the cells where it is gener-
ated, primarily hepatocytes [96–99]. As a consequence, TT1 
is characterized by progressive liver disease, and could be 
classified into different categories based on their moment of 
presentation, associated symptomatology, and resulting out-
come [5]. The majority of the patients presented (very) early 
with severe acute liver failure and associated pronounced 
coagulopathy, ascites (with or without spontaneous bacterial 
peritonitis) due to low albumin concentrations, and hypo-
glycemia. In particular, these early presenting patients had 
a poor outcome, with only 10–30% of the patients still alive 
2 years after diagnosis [5, 100]. In later presenting patients, 
liver problems are usually less pronounced, although HCC 
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could be present already [5, 101–105]. When patients sur-
vived the initial period, there was a high risk for developing 
chronic liver disease, cirrhosis, and eventually HCC when 
treated with a phenylalanine/tyrosine-restricted diet only [5, 
6, 104]. Therefore, OLT was long considered the only defini-
tive option to prevent metabolic and oncological problems 
[8–10, 103, 106–110].
The introduction of NTBC results in a quick recovery 
of liver function, although about 10% of the patients with 
(acute) liver failure do not respond to the treatment [12, 31, 
50, 83, 111]. In most patients, the coagulopathy quickly 
resolves, porphobilinogen synthase activity reaches normal 
levels within a month, 5-ALA excretion in urine normalizes 
in most cases, and urinary and blood SA concentrations nor-
malize completely after some days or months, respectively 
[11, 31, 83, 112]. Alfa-fetoprotein (AFP), the biochemical 
marker for HCC in TT1, decreased slowly over some months 
to normal values. The risk of liver cancer (mainly HCC, 
although hepatoblastoma could occur) decreased tremen-
dously and is estimated to be around 1% if NTBC treatment 
is initiated early [11, 13, 31, 83, 113]. In line with this, long-
term follow-up revealed that NTBC-treated TT1 patients are 
still at risk for HCC, especially when NTBC is initiated late 
due to delayed diagnosis or unavailability of NTBC [13, 31, 
46, 55, 114–121].
So far, no HCC development in pre-clinically treated 
patients has been reported [13, 120, 122–124]. However, 
HCC is still seen in TT1 mice, even if NTBC is started pre-
natally and high amounts are given after birth in combi-
nation with a phenylalanine/tyrosine-restricted diet [125, 
126]. In addition, gene expression patterns and collagen 
metabolism are also not fully normalized in TT1 patients 
receiving NTBC [127, 128]. Due to this increased risk to 
develop HCC, screening is still recommended using regu-
lar AFP measurements and imaging such as ultrasound and 
magnetic resonance imaging (MRI) in case of a suspect 
lesion [14, 32, 45, 82, 123, 124]. In contrast to other dis-
eases with a high risk of developing HCC (e.g., hepatitis B 
and C), AFP has always been considered a reliable marker 
for liver cancer in TT1 [14, 113, 115]. However, HCC may 
develop without clear rise in AFP and additional markers 
are currently being investigated [118, 124, 129]. Thus, at 
present, both a lesion at imaging and a rise in AFP should be 
considered pathognomonic for HCC, while a slow decrease 
of AFP, or an AFP level that remains above the upper limit 
of normal after 2 years of age are predictive signs of HCC 
development and should be discussed with the OLT team as 
well [115, 118].
6.2  Renal Problems
FAA not only affects hepatocytes, but tubular cells of 
the kidney as well. FAA can cause oxidative stress, acute 
apoptosis, and cellular death in proximal tubular cells just 
as in hepatocytes [130]. In addition, SA has been shown to 
reduce sugar and amino acid uptake in the proximal tubulus 
leading to renal Fanconi syndrome [130, 131]. In contrast 
to liver failure, these renal tubular problems are apparent 
as well in late-presenting TT1 patients [45]. The charac-
teristic renal disease in TT1 patients is a renal tubulopathy 
with aminoaciduria, glucosuria, phosphaturia, and acido-
sis (that is difficult to fully correct) and, as a consequence, 
secondary hypophosphatemic (vitamin D-resistant) rickets 
may develop. However, the severity of the renal problems 
varies significantly between patients [45, 50, 55, 132]. Die-
tary restriction of phenylalanine and tyrosine and supple-
mentation of minerals and vitamins seem to improve renal 
tubular defects (even without NTBC) in some patients. In 
dietary-treated patients, this partial response together with 
non-adherence may result in progression to nephromegaly, 
nephrocalcinosis, glomerulosclerosis, or even renal failure 
[133–138].
Administration of NTBC in patients with renal tubular 
dysfunction results in an improvement in kidney function 
with normalization of phosphate reabsorption and plasma 
phosphate concentrations, usually within a month [11, 136, 
139], although sometimes less rapidly than for the liver 
problems. A slower but continuous improvement could be 
seen in other parameters such as glucosuria, proteinuria, 
excretion of macroglobulin, plasma uric acid, plasma cal-
cium, and rickets within the following years; mineral and 
vitamin supplements could usually be withdrawn [111, 132, 
136, 139, 140]. Long-term follow-up of adequately NTBC-
treated patients revealed a normal tubular function in most 
of the patients [34, 132, 138], although minor tubulopathy 
without clinical consequences and already existing nephroc-
alcinosis may persist [46, 50, 51, 132, 136]. In pre-clinically 
diagnosed patients, none of the patients showed clinically 
significant renal problems at diagnosis or developed renal 
problems while on NTBC [13, 122]. Annual clinical follow-
up with laboratory evaluation and renal ultrasound is recom-
mended for TT1 patients [32, 45].
6.3  Neurological Problems
Recurrent neurological crises could be present in up to 40% 
of the TT1 patients treated by diet alone and were a main 
cause of hospitalization or even mortality [5, 7]. The neu-
rological crises were usually provoked by a minor infection 
and presented as a peripheral neuropathy with hypertonia, 
paralytic ileus with vomiting, or muscle weakness that could 
progress to paralysis or even respiratory failure that could 
mimic the progressive weakness in Guillain–Barre syn-
drome [7, 141].
Treatment with NTBC results in a rapid decline in SA, 
resulting in an increase in porphobilinogen synthase activity 
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and, as a consequence, normalization of 5-ALA concentra-
tions that were thought to be responsible for the neurological 
crises or so-called porphyria-like-syndrome [7, 11]. As a 
result, the neurological symptoms have completely disap-
peared after the start of NTBC treatment [13, 31, 50, 141]. 
However, when NTBC treatment is interrupted, severe neu-
rological crises may reappear, mimicking the porphyria-like-
syndrome described above.
6.4  Neuropsychological Problems
No consistent cognitive or behavioral deficiencies were 
reported in TT1 patients prior to the introduction of NTBC. 
In contrast, intellectual development and school performance 
was considered to be normal, even in patients with recurrent 
neurological crises. However, in more recent years, after the 
introduction of NTBC, several studies reported a non-opti-
mal cognitive development in TT1 patients. In 2008, 35% of 
French TT1 patients retrospectively showed school problems 
[50]. Later research showed a broad range of neurocognitive 
problems, especially in children with TT1. These neurocog-
nitive problems include a lower (performance and verbal) 
IQ [46, 119, 142–144] and even regression of IQ over time 
[145, 146], abnormal motor skills [143, 147], impaired 
executive functioning (including affected working memory 
and cognitive flexibility), and non-optimal social cognition 
[144, 147] and behavioral problems such as attention defi-
cits [148]. Next to these neurocognitive problems, structural 
changes in the brain are found in some TT1 patients. MRI of 
two TT1 patients showed white matter problems and myeli-
nation deficits [149, 150] and positron emission tomogra-
phy/computed tomography scans showed abnormal bilateral 
hypometabolism in one out of three adult patients [147]. 
However, this is contradicted by the study of Thimm et al. 
that showed no MRI abnormalities [143]. Various hypoth-
eses have been suggested to explain these neurocognitive 
disturbances: (i) the disease itself, with toxic products and 
associated liver failure [151, 152], (ii) treatment with NTBC, 
(iii) high plasma tyrosine concentrations either being toxic 
in itself or changing neurotransmitter metabolism, (iv) high 
plasma tyrosine concentrations that compete with the uptake 
of other amino acids and thus impair cerebral protein synthe-
sis in general or impair neurotransmitter synthesis caused by 
decreased brain influx of tryptophan, or (v) low plasma and 
corresponding brain phenylalanine concentrations [141]. To 
test these different hypotheses, associations between the neu-
rocognitive deficiencies and alterations of blood TT1 pheny-
lalanine or tyrosine concentrations have been sought. So far, 
no specific group of TT1 patients at risk for neurocognitive 
deficiencies could be identified, as non-optimal neurocogni-
tive outcomes have been seen in pre-clinically diagnosed, 
clinically diagnosed, and transplanted patients [144, 153]. 
Also, a correlation between low blood phenylalanine or low 
phenylalanine/tyrosine ratio and neurocognitive outcome 
was found only in two studies [142, 146]. To investigate this 
further, Thimm et al. measured increased tyrosine concentra-
tions in cerebral spinal fluid while 5-HIAA concentrations 
were decreased, possibly indicating central nervous system 
serotonin deficiency, but no direct measurement of brain 
serotonin has been made in TT1 [154].
During clinical follow-up, psychomotor and intelligence 
testing is rarely routinely performed [45], although it has 
been advised to perform neuropsychological testing before 
school age and at regular intervals afterwards [14, 32].
6.5  Other Symptoms
Hypertrophic obstructive cardiomyopathy has been a rarely 
reported symptom in TT1 patients treated with a phenylala-
nine/tyrosine-restricted diet [104, 155, 156], which report-
edly resolves completely within some months after start of 
NTBC treatment [157–159]. Other rare reported accompany-
ing symptoms at diagnosis include transient carnitine defi-
cient myopathy, likely caused by renal Fanconi tubulopathy 
[160], and transient hyperinsulinism with hypertrophy of the 
islets of Langerhans [100, 161]. To date, there have been no 
reports of adverse cardiac symptoms while taking NTBC 
[158], nor about any other of the rarely reported complica-
tions mentioned above.
7  Future Considerations and Remaining 
Challenges for TT1
7.1  Pregnancy
With the tremendously improved clinical outcome and sur-
vival probability, pregnancy in TT1-affected mothers treated 
with NTBC have been reported [162–164]. Not much is 
known about a possible teratogenic effect of NTBC. How-
ever, very high dosages of NTBC have been associated with 
corneal lesions, malformations, and reduced survival in 
offspring of NTBC-treated laboratory animals [162], while 
prenatally prescribed normal dosages do prevent early death 
in TT1 mice and pigs without any teratogenicity [57, 165].
In human pregnancies, NTBC has been continued in all 
three reported cases. Two unaffected children had a normal 
birth weight, while the birth weight of one child with TT1 
was in the low normal range. All three infants were healthy 
without signs of malformations and had normal develop-
ment later on while receiving between 0.5 and 1.0 mg/kg 
NTBC during pregnancy with maternal tyrosine concen-
trations up to 700–800 µmol/L [162–164]. After delivery, 
neonatal blood NTBC concentrations reduced slowly while 
receiving bottle feeding [163, 164], until SA became detect-
able in urine and AFP concentrations rose slightly after an 
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initial decline 2 weeks after birth in the TT1-affected child 
[162]. All reported TT1 mothers were healthy with no sign 
of liver, renal or neurological deterioration during pregnancy 
[162–164].
Although no clear guidelines exist and existing data is 
limited, current knowledge suggests that NTBC treatment 
in pregnant TT1 patients should be continued with strict 
monitoring considering the possible complications for the 
pregnant TT1 patient associated with an interruption in 
NTBC treatment [48].
7.2  Long‑Term Follow‑Up
With the introduction of NTBC, the outcome of TT1 patients 
improved considerably as explained above. As about 10% 
of the patients presenting with liver failure do not respond 
early enough to NTBC to prevent OLT, and the risk of HCC 
is still clearly elevated when NTBC treatment is started late, 
a further improvement reduction in liver-related morbidity is 
expected with the universal introduction of neonatal screen-
ing [13, 122]. With early introduction of NTBC, important 
clinical symptomatology can be prevented, although the 
very long-term effects of NTBC, both in terms of effective-
ness and toxicity, remain to be evaluated. At this time, it is 
clear that strict follow-up for possible HCC is still needed 
as it is not certain whether NTBC only delays the develop-
ment of HCC or completely prevents HCC formation when 
started after pre-clinical neonatal diagnosis. However, in 
light of the uncertain long-term effectiveness and potential 
new toxicities, strict monitoring of the disease is of crucial 
importance. This is hampered by the fact that no clear guide-
lines on effective dosing and safe concentrations of NTBC 
and safe concentrations of biochemical parameters such as 
blood or urine SA, and blood tyrosine and phenylalanine 
concentrations currently exist. Therefore, neurocognitive, 
psychosocial, ophthalmic, physical, and nutritional follow-
up is necessary to prevent complications of high tyrosine 
concentrations and to assess vitamin and mineral status. 
Furthermore, continued research is necessary to address 
the neurocognitive functioning, its relationship with current 
treatment strategies, and to reveal the pathophysiological 
mechanisms causing the brain impairments.
7.3  Considerations from a Cost Perspective
NTBC is one of the 20 most expensive drugs [166], with 
reported annual costs between US $70,000 and US $140,000 
for a person of 50 kg depending on manufacturer and coun-
try of issue [167, 168]. Despite this, only one cost-effective-
ness study has been performed [169]. As a consequence of 
the improved clinical outcome, NTBC lowered the utiliza-
tion of health care and associated costs for hospital visits 
and admissions, although total yearly costs increased sig-
nificantly with NTBC treatment [169].
Developing drugs for rare diseases, the so-called orphan 
drugs (affecting < 1:2000 individuals according to criteria in 
the EU) has been—and still is—an unmet need in many of 
those rare and ultra-rare diseases. However, with the adop-
tion of Regulation (EC) No. 141/2000 in the EU, many new 
orphan drugs are coming to market every year as a result of 
intensifying rare disease research and drug development. 
Incentives for companies, including fee reductions and, 
importantly, 10-year market exclusivity, has stimulated this 
development. In combination with an emphasis on person-
alized medicine as a consequence of advances in (genetic) 
technology, the drug market is switching towards develop-
ment of orphan medicines.
Although patients, families, and healthcare professionals 
welcome more treatment options, this increasing ‘orphani-
zation’ of the healthcare system has fueled concerns among 
regulatory bodies, payers, healthcare professionals, and 
patients because of the high prices. A major concern in 
this respect is the observation that some orphan medicines 
reach the market in an immature stage: while pivotal trials 
show promising results, insufficient knowledge of long-term, 
clinically relevant outcomes and the price in itself withholds 
reimbursement, which leads to unequal access to orphan 
drugs [170]. Hence, new pharmaceutical developmental 
models need to be developed, including better and more 
independent evaluation of outcomes, for example in adap-
tive pathway models [171] as well as reimbursement models, 
taking cost effectiveness, uncertainty, and development costs 
into consideration. With regard to NTBC, all of the above 
applies; uncertainty of long-term effectiveness and toxicity 
requires improved, collaborative monitoring, with open data 
sharing and independent outcome analysis. This is important 
to support healthcare professionals to make rational choices 
for treatment for the benefit of their patients: at this time, 
partly because of costs, some centers advocated to perform 
OLT instead of the conservative treatment with NTBC and 
a combined phenylalanine/tyrosine-restricted diet.
7.4  Possible New Strategies
So far, no HCC has been reported in pre-clinically diag-
nosed TT1 patients. However, as FAH is expressed in utero 
and AFP concentrations are raised at birth, a prenatal start 
to liver disease is likely [57, 172, 173]. Therefore, prena-
tal diagnosis and prevention of prenatal liver disease could 
theoretically be achieved with the prescription of NTBC 
to unaffected mothers. Alternatively, recent advances have 
shown in utero gene editing to abolish neonatal lethal liver 
disease in TT1 mice [174]. As TT1 mice still develop HCC 
even if 90–95% of the liver cells are corrected, long-term 
efficacy of cell or gene therapy was thought to require all 
Long-Term Outcomes of Treatment with NTBC in Tyrosinemia Type 1
liver cells to be targeted to prevent HCC formation in origi-
nal FAH deficient cells [125, 175]. However, liver-directed 
gene therapy in a TT1 pig has been shown to be effective 
without signs of liver fibrosis or HCC development after 
3 years of follow-up and could thus be a potential alternative 
therapeutic approach that needs to be explored [176].
8  Conclusion
This review showed that NTBC has clearly improved the 
treatment and outcomes for patients with TT1. During the 
last 25 years, NTBC treatment has proved to be generally 
safe, well tolerated, and effective. Where OLT was once con-
sidered the only definitive option, OLT is now only used in 
cases that fail to respond to NTBC and when liver cancer 
develops. To further reduce the risk of long-term complica-
tions such as HCC and neurocognitive issues, and to prevent 
clinical symptoms, pre-clinical diagnosis with blood spot 
SA measurements in newborn screening is necessary. The 
exact risks for the development of complications associated 
with the disease, NTBC, and long-term dietary treatment 
are not known yet and therefore strict follow-up is neces-
sary. Future challenges will be to develop uniform guidelines 
for treatment and follow-up, reliable detection of possible 
liver cancer, and weighing the risks, challenges, and costs of 
existing and alternative strategies for the treatment of TT1.
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